非小细胞肺癌组织ABCG4表达与耐药的相关性研究

Expression of ABCG4 in NSCLC and its correlation with chemorsistance of NSCLC

目的:探讨ABC膜转运蛋白ABCG4在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理因素和化疗药物敏感性的相关性。方法:免疫组化EnVinsion法、免疫荧光法检测AB-CG4在92例NSCLC组织中的表达,激光共聚焦显微镜观察其定位;MTT法检测相应癌组织对化疗药物的敏感性,分析其与ABCG4表达的相关性。结果:ABCG4阳性表达主要定位于胞膜和胞质,鳞癌阳性率为67.3%(33/49),腺癌为81.4%(35/43),两者差异有统计学意义,P=0.001;鳞癌Ⅱ期阳性率为41.7%(10/24),Ⅱ～Ⅲ期为92.0%(23/25),差异有统计学意义,P=0.000;腺癌中高分化阳性率为76.7%(23/30),低分化为92.3%(12/13),差异有统计学意义,P=0.033。环磷酰胺、吉西他滨、多柔比星、紫杉醇和顺铂在NSCLC组织中药物敏感性试验结果与其相应组织AB-CG4表达相关性检验,P均<0.05,rs均<-0.3,其中鳞癌中rs除紫杉醇外(-0.23)均<-0.3,而腺癌也均<-0.3。结论:ABCG4在NSCLC组织中高表达,表达的高低与病理分类、分级有关,并很可能与NSCLC化疗药物耐药有关。

OBJECTIVE： To investigate the expression of ABCG4 protein in non-small cell lung cancer （NSCLC）, and the correlation with chemoresistance and clinical characteristics. METHODS： The expression rate of ABCG4 was detected in 92 cases of NSCLC by the immunohistochemical method and immunofluorescent method, and the location of the protein expression was observed under a light microscope and confocal laser scanning microscope. The chemoresistace of the same cases was assayed by the MTT method, and the correlation of the chemoresistance with expression of ABCG4 in NSCLC was analyzed statistically. RESULTS： The ABCG4 protein was overexpressed with the 67.3% （33/49） and 81.4%（35/43） positive rates in squamous cell lung cancer and lung adenocarcinoma respectively, P=0. 001. The positive expression rates of pathological grade Ⅱ and Ⅱ- Ⅲ were 41.7% （10/24） and 92.0% （23/25） respectively in squamous cell lung cancer with a high statistical significance for their comparison, P=0. 000; and the positive expression rates of moderately and low differentiated lung adenocarcinoma were 76.7%（23/30） and 92.3%（12/13） respectively with a significant difference for their comparison, P= 0. 033. The P values of the correlation test among the chemosensitivities of cyclophamide, gemcitabine, adriamycin, paclitaxel and cisplatin with ABCG4 expression in NSCLC were all below 0.05, and the correlation coefficients （rs） were all bellow -0.3, and their rs were also bellow -0.3 （except for that between chemosensitivity of paclitaxe and ABCG4） in the squamous cell lung cancer and were all bellow - 0.3 in lung adenocarcinoma. CONCLUSION： The ABCG4 protein is overexpression in NSCLC with the expression rate being higher in lung adenocareinoma than that in the squamous cell lung cancer, and the chemoresistance in NSCLC is proba bly correlated with the ABCG4 expression.